GlassScriptPhysician profile
Daniel Brock
NPI 1285848614
$5,876.12
in general payments reported to CMS, 2019-2025
33 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $934 · 2021: $1,382 · 2022: $685 · 2023: $785 · 2024: $1,047 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $852.63 | 2019-2025 | |
| Novo Nordisk INC | $716.21 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $705.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $655.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $488.41 | 2019-2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $397.83 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $363.79 | 2019-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Abbvie INC. | $349.45 | 2020-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.31 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $158.22 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $112.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.86 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $85.77 | 2020-2024 | Eliquis |
| Exact Sciences Corporation | $70.83 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $66.57 | 2021-2024 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $63.53 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.54 | 2022 | |
| Boston Scientific Corporation | $54.67 | 2023 | |
| Radius Health, INC. | $53.58 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $47.48 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $46.24 | 2021 | |
| Axsome Therapeutics, INC. | $43.54 | 2024-2025 | Symbravo, Auvelity |
| Astellas Pharma US INC | $40.32 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $31.96 | 2023 | Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.86 | 2019-2020 | |
| Lundbeck LLC | $19.39 | 2023 | Rexulti |
| Genzyme Corporation | $17.63 | 2021 | |
| Antares Pharma, INC. | $15.83 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.92 | 2024 | Iovera, Zilretta |
| Clarus Therapeutics INC. | $12.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.92 | 2022 | |
| Circassia INC. | $12.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.